Tenax Therapeutics, Inc. (NASDAQ:TENX) Given Average Recommendation of “Buy” by Brokerages

Tenax Therapeutics, Inc. (NASDAQ:TENX) has been given a consensus rating of “Buy” by the five ratings firms that are covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $170.67.

TENX has been the topic of a number of analyst reports. StockNews.com assumed coverage on shares of Tenax Therapeutics in a research report on Thursday, September 26th. They issued a “sell” rating on the stock. Leerink Partners assumed coverage on shares of Tenax Therapeutics in a research report on Thursday, October 24th. They set an “outperform” rating and a $16.00 price target on the stock. Leerink Partnrs upgraded shares of Tenax Therapeutics to a “strong-buy” rating in a research report on Thursday, October 24th. William Blair initiated coverage on Tenax Therapeutics in a report on Monday, September 30th. They set an “outperform” rating on the stock. Finally, Guggenheim initiated coverage on Tenax Therapeutics in a report on Monday, October 14th. They issued a “buy” rating and a $16.00 price target for the company.

Tenax Therapeutics Trading Up 2.1 %

Shares of Tenax Therapeutics stock opened at $4.39 on Friday. The firm has a fifty day moving average of $3.81 and a two-hundred day moving average of $3.60. Tenax Therapeutics has a 52 week low of $2.77 and a 52 week high of $61.20.

Tenax Therapeutics (NASDAQ:TENX) last released its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) EPS for the quarter, beating analysts’ consensus estimates of ($1.99) by $0.16. Sell-side analysts predict that Tenax Therapeutics will post -6.62 earnings per share for the current year.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.